Literature DB >> 11576932

Advanced glycation end products and the progressive course of renal disease.

A Heidland1, K Sebekova, R Schinzel.   

Abstract

In experimental and human diabetic nephropathy (DN), it has been shown that advanced glycation end products (AGEs), in particular, carboxymethyl-lysine and pentosidine, accumulate with malondialdehyde in glomerular lesions in relation to disease severity and in the presence of an upregulated receptor for AGE (RAGE) in podocytes. Toxic effects of AGEs result from structural and functional alterations in plasma and extracellular matrix (ECM) proteins, in particular, from cross-linking of proteins and interaction of AGEs with their receptors and/or binding proteins. In mesangial and endothelial cells, the AGE-RAGE interaction caused enhanced formation of oxygen radicals with subsequent activation of nuclear factor-kappaB and release of pro-inflammatory cytokines (interleukin-6, tumor necrosis factor-alpha), growth factors (transforming growth factor-beta1 [TGF-beta1], insulin-like growth factor-1), and adhesion molecules (vascular cell adhesion molecule-1, intercellular adhesion molecule-1). In tubular cells, incubation with AGE albumin was followed by stimulation of the mitogen-activating protein (MAP) kinase pathway and its downstream target, the activating protien-1 (AP-1) complex, TGF-beta1 overexpression, enhanced protein kinase C activity, decreased cell proliferation, and impaired protein degradation rate, in part caused by decreased cathepsin activities. The pathogenic relevance of AGEs was further verified by in vivo experiments in euglycemic rats and mice by the parenteral administration of AGE albumin, leading in the glomeruli to TGF-beta1 overproduction, enhanced gene expression of ECM proteins, and morphological lesions similar to those of DN. Evidence for the pathogenic relevance of AGEs in DN also comes from experimental studies in which the formation and/or action of AGEs was modulated by aminoguanidine, OPB-9195, pyridoxamine, soluble RAGEs, serine protease trypsin, and antioxidants, resulting in improved cell and/or renal function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11576932     DOI: 10.1053/ajkd.2001.27414

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  36 in total

Review 1.  Pathogenesis of diabetic nephropathy.

Authors:  Claudia van Dijk; Tomas Berl
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

Review 2.  The aging kidney: a review -- part I.

Authors:  Fred G Silva
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

Review 3.  The aging kidney: a review--part II.

Authors:  Fred G Silva
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

Review 4.  Immune and inflammatory role in renal disease.

Authors:  John D Imig; Michael J Ryan
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090

5.  Continuous renal replacement therapy with a polymethyl methacrylate membrane hemofilter suppresses inflammation in patients after open-heart surgery with cardiopulmonary bypass.

Authors:  Hiroshi Mukaida; Satoshi Matsushita; Takahiro Inotani; Atsushi Nakamura; Atsushi Amano
Journal:  J Artif Organs       Date:  2018-02-05       Impact factor: 1.731

Review 6.  Transforming growth factor-β and atherosclerosis: interwoven atherogenic and atheroprotective aspects.

Authors:  Ian Toma; Timothy A McCaffrey
Journal:  Cell Tissue Res       Date:  2011-05-31       Impact factor: 5.249

Review 7.  Extracellular matrix roles in cardiorenal fibrosis: Potential therapeutic targets for CVD and CKD in the elderly.

Authors:  Hiroe Toba; Merry L Lindsey
Journal:  Pharmacol Ther       Date:  2018-08-25       Impact factor: 12.310

8.  LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats.

Authors:  J L Figarola; S Scott; S Loera; C Tessler; P Chu; L Weiss; J Hardy; S Rahbar
Journal:  Diabetologia       Date:  2003-07-05       Impact factor: 10.122

9.  Visfatin and endogenous secretory receptor for advanced glycation end-products in diabetic type 2 and non-diabetic patients undergoing intermittent hemodialysis.

Authors:  Leszek Niepolski; Alicja E Grzegorzewska; Monika Młot-Michalska
Journal:  Int Urol Nephrol       Date:  2009-01-31       Impact factor: 2.370

10.  Role of inflammation in túbulo-interstitial damage associated to obstructive nephropathy.

Authors:  María T Grande; Fernando Pérez-Barriocanal; José M López-Novoa
Journal:  J Inflamm (Lond)       Date:  2010-04-22       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.